# Arun Krishnan

#### List of Publications by Citations

Source: https://exaly.com/author-pdf/1860957/arun-krishnan-publications-by-citations.pdf

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

141<br/>papers4,494<br/>citations35<br/>h-index63<br/>g-index149<br/>ext. papers5,187<br/>ext. citations6.4<br/>avg, IF5.58<br/>L-index

#	Paper	IF	Citations
141	Chemotherapy-induced peripheral neurotoxicity: a critical analysis. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2013</b> , 63, 419-37	220.7	410
140	Riluzole, neuroprotection and amyotrophic lateral sclerosis. Current Medicinal Chemistry, 2010, 17, 1942	! <b>-4.9</b> 9	193
139	Oxaliplatin-induced neurotoxicity and the development of neuropathy. <i>Muscle and Nerve</i> , <b>2005</b> , 32, 51-6	5 <b>9</b> .4	170
138	Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. <i>Brain</i> , <b>2009</b> , 132, 2712-23	11.2	155
137	Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. <i>Current Medicinal Chemistry</i> , <b>2008</b> , 15, 3081-94	4.3	150
136	Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. <i>Oncologist</i> , <b>2011</b> , 16, 708-16	5.7	148
135	Uremic neuropathy: clinical features and new pathophysiological insights. <i>Muscle and Nerve</i> , <b>2007</b> , 35, 273-90	3.4	144
134	Axonal ion channels from bench to bedside: a translational neuroscience perspective. <i>Progress in Neurobiology</i> , <b>2009</b> , 89, 288-313	10.9	131
133	Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1243-9	2.2	125
132	Neurological complications of chronic kidney disease. <i>Nature Reviews Neurology</i> , <b>2009</b> , 5, 542-51	15	116
131	Bellß palsy: aetiology, clinical features and multidisciplinary care. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2015</b> , 86, 1356-61	5.5	107
130	Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. <i>Brain</i> , <b>2013</b> , 136, 1361-70	11.2	102
129	Altered nerve excitability properties in established diabetic neuropathy. <i>Brain</i> , <b>2005</b> , 128, 1178-87	11.2	101
128	Altered motor nerve excitability in end-stage kidney disease. <i>Brain</i> , <b>2005</b> , 128, 2164-74	11.2	95
127	Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. <i>Brain</i> , <b>2008</b> , 131, 1209-16	11.2	72
126	Oxaliplatin and axonal Na+ channel function in vivo. Clinical Cancer Research, 2006, 12, 4481-4	12.9	68
125	Nerve function and dysfunction in acute intermittent porphyria. <i>Brain</i> , <b>2008</b> , 131, 2510-9	11.2	66

Neurological complications in chronic kidney disease. JRSM Cardiovascular Disease, 2016, 5, 204800401667768765 124 Differentiating lower motor neuron syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 58 123 5.5 **2017**, 88, 474-483 Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of 122 3.7 57 neurotoxicity. PLoS ONE, 2011, 6, e18469 The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. 121 3.7 55 Brain Research, **2009**, 1273, 39-47 Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. 120 14.4 53 Cancer Treatment Reviews, 2016, 50, 118-128 Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal 8.7 119 53 transplant recipients. American Journal of Transplantation, 2013, 13, 2426-32 Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced 118 52 3.4 neuropathy. Muscle and Nerve, 2011, 43, 367-74 Mutation in the Na+ channel subunit SCN1B produces paradoxical changes in peripheral nerve 117 11.2 51 excitability. Brain, 2005, 128, 1841-6 Assessment of nerve excitability in toxic and metabolic neuropathies. Journal of the Peripheral 116 4.7 50 Nervous System, 2008, 13, 7-26 Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes. JAMA Neurology, 2018, 115 17.2 47 75, 980-988 Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic 114 46 inflammatory demyelinating polyneuropathy. Archives of Neurology, 2011, 68, 862-9 Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a 3.9 45 systematic review and Delphi survey. Supportive Care in Cancer, 2017, 25, 3485-3493 Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. 112 5.5 44 Journal of Neurology, Neurosurgery and Psychiatry, **2007**, 78, 1202-8 Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes. Diabetes, 0.9 42 2012, 61, 1592-8 Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models. 110 41 Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 33-8 The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with 38 109 17.2 multiple sclerosis. JAMA Neurology, 2014, 71, 1386-93 Sensory nerve excitability and neuropathy in end stage kidney disease. Journal of Neurology, 108 38 5.5 Neurosurgery and Psychiatry, 2006, 77, 548-51 Nerve excitability properties in lower-limb motor axons: evidence for a length-dependent gradient. 107 3.4 37 Muscle and Nerve, **2004**, 29, 645-55

106	Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. <i>Clinical Neurophysiology</i> , <b>2012</b> , 123, 2460-7	4.3	35
105	The pathophysiology of oxaliplatin-induced neurotoxicity. <i>Current Medicinal Chemistry</i> , <b>2006</b> , 13, 2901-	7 4.3	35
104	Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease. <i>Clinical Neurophysiology</i> , <b>2014</b> , 125, 179-85	4.3	33
103	Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. <i>Clinical Neurophysiology</i> , <b>2017</b> , 128, 1166-1175	4.3	32
102	Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2017</b> , 12, 1569-1577	6.9	32
101	Measurement of axonal excitability: Consensus guidelines. <i>Clinical Neurophysiology</i> , <b>2020</b> , 131, 308-323	4.3	31
100	Longitudinal plasticity across the neural axis in acute stroke. <i>Neurorehabilitation and Neural Repair</i> , <b>2013</b> , 27, 219-29	4.7	30
99	Neuropathy, axonal Na+/K+ pump function and activity-dependent excitability changes in end-stage kidney disease. <i>Clinical Neurophysiology</i> , <b>2006</b> , 117, 992-9	4.3	30
98	Exploring the Evolution of Cortical Excitability Following Acute Stroke. <i>Neurorehabilitation and Neural Repair</i> , <b>2016</b> , 30, 244-57	4.7	29
97	Effects of axonal ion channel dysfunction on quality of life in type 2 diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36, 1272-7	14.6	28
96	Neuromuscular disease in the dialysis patient: an update for the nephrologist. <i>Seminars in Dialysis</i> , <b>2009</b> , 22, 267-78	2.5	28
95	Sonographic differences in carpal tunnel syndrome with normal and abnormal nerve conduction studies. <i>Journal of Clinical Neuroscience</i> , <b>2016</b> , 34, 77-80	2.2	27
94	Axonal dysfunction prior to neuropathy onset in type 1 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2013</b> , 29, 53-9	7.5	27
93	Mechanisms of axonal dysfunction in diabetic and uraemic neuropathies. <i>Clinical Neurophysiology</i> , <b>2013</b> , 124, 2079-90	4.3	25
92	Association between glycemic variability and peripheral nerve dysfunction in type 1 diabetes. <i>Muscle and Nerve</i> , <b>2016</b> , 54, 967-969	3.4	24
91	Conduction block and impaired axonal function in tick paralysis. <i>Muscle and Nerve</i> , <b>2009</b> , 40, 358-62	3.4	24
90	Ischaemic sensitivity of axons in carpal tunnel syndrome. <i>Journal of the Peripheral Nervous System</i> , <b>2009</b> , 14, 190-200	4.7	24
89	Axonal function and activity-dependent excitability changes in myotonic dystrophy. <i>Muscle and Nerve</i> , <b>2006</b> , 33, 627-36	3.4	24

## (2008-2006)

88	Ischaemia induces paradoxical changes in axonal excitability in end-stage kidney disease. <i>Brain</i> , <b>2006</b> , 129, 1585-92	11.2	22
87	Axonal excitability properties in hemifacial spasm. <i>Movement Disorders</i> , <b>2007</b> , 22, 1293-8	7	21
86	Motor unit remodelling in multifocal motor neuropathy: The importance of axonal loss. <i>Clinical Neurophysiology</i> , <b>2017</b> , 128, 2022-2028	4.3	20
85	Botulinum toxin modulates cortical maladaptation in post-stroke spasticity. <i>Muscle and Nerve</i> , <b>2013</b> , 48, 93-9	3.4	19
84	Changes in human sensory axonal excitability induced by an ischaemic insult. <i>Clinical Neurophysiology</i> , <b>2008</b> , 119, 2054-63	4.3	19
83	Utility of maximum perfusion intensity as an ultrasonographic marker of intraneural blood flow.  Muscle and Nerve, <b>2017</b> , 55, 77-83	3.4	18
82	Tear film substance P: A potential biomarker for diabetic peripheral neuropathy. <i>Ocular Surface</i> , <b>2019</b> , 17, 690-698	6.5	18
81	Segmental facial anhidrosis and tonic pupils with preserved deep tendon reflexes: a novel autonomic neuropathy. <i>Journal of Neuro-Ophthalmology</i> , <b>2005</b> , 25, 5-8	2.6	18
80	Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. <i>BMC Cancer</i> , <b>2014</b> , 14, 993	4.8	17
79	The Effect of Diabetes on Cortical Function in Stroke: Implications for Poststroke Plasticity. <i>Diabetes</i> , <b>2017</b> , 66, 1661-1670	0.9	16
78	Sleep-Disordered Breathing in People with Multiple Sclerosis: Prevalence, Pathophysiological Mechanisms, and Disease Consequences. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 740	4.1	16
77	Oxaliplatin-induced lhermitteß phenomenon as a manifestation of severe generalized neurotoxicity. <i>Oncology</i> , <b>2009</b> , 77, 342-8	3.6	16
76	Riche-Cannieu anastomosis as an inherited trait. Clinical Neurophysiology, 2007, 118, 770-5	4.3	16
75	Hypokalemic weakness in hyperaldosteronism: activity-dependent conduction block. <i>Neurology</i> , <b>2005</b> , 65, 1309-12	6.5	16
74	Correlation between markers of peripheral nerve function and structure in type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2018, 34, e3028	7.5	15
73	Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 385-91	5	15
<del>72</del>	Effects of hemodiafiltration and high flux hemodialysis on nerve excitability in end-stage kidney disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e59055	3.7	15
71	Axonal function in a family with episodic ataxia type 2 due to a novel mutation. <i>Journal of Neurology</i> , <b>2008</b> , 255, 750-5	5.5	15

70	Acute transverse myelitis in SLE. <i>Neurology</i> , <b>2004</b> , 62, 2087-	6.5	15
69	In vivo evidence of reduced nodal and paranodal conductances in type 1 diabetes. <i>Clinical Neurophysiology</i> , <b>2016</b> , 127, 1700-1706	4.3	15
68	Relationship between corneal confocal microscopy and markers of peripheral nerve structure and function in Type 2 diabetes. <i>Diabetic Medicine</i> , <b>2020</b> , 37, 326-334	3.5	15
67	Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. <i>Experimental Neurology</i> , <b>2011</b> , 227, 120-7	5.7	14
66	Acute, reversible axonal energy failure during stroke-like episodes in MELAS. <i>Pediatrics</i> , <b>2010</b> , 126, e73	84 <del>-7</del> 94	14
65	Continuous subcutaneous insulin infusion preserves axonal function in type 1 diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2015</b> , 31, 175-82	7.5	13
64	Excitability differences in lower-limb motor axons during and after ischemia. <i>Muscle and Nerve</i> , <b>2005</b> , 31, 205-13	3.4	13
63	Motor cortex excitability in acute cerebellar infarct. <i>Cerebellum</i> , <b>2013</b> , 12, 826-34	4.3	12
62	Axonal dysfunction with voltage gated potassium channel complex antibodies. <i>Experimental Neurology</i> , <b>2014</b> , 261, 337-42	5.7	11
61	Porphyric neuropathy. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2013</b> , 115, 613-27	3	11
60	Central sleep apnea in multiple sclerosis: a pilot study. Sleep and Breathing, 2017, 21, 691-696	3.1	10
59	Conduction block in immune-mediated neuropathy: paranodopathy versus axonopathy. <i>European Journal of Neurology</i> , <b>2019</b> , 26, 1121-1129	6	10
58	Axonal dysfunction, dysmyelination, and conduction failure in hereditary neuropathy with liability to pressure palsies. <i>Muscle and Nerve</i> , <b>2014</b> , 49, 858-65	3.4	10
57	Haemodialysis alters peripheral nerve morphology in end-stage kidney disease. <i>Clinical Neurophysiology</i> , <b>2017</b> , 128, 281-286	4.3	10
56	A Comparative Study on the Diagnostic Utility of Corneal Confocal Microscopy and Tear Neuromediator Levels in Diabetic Peripheral Neuropathy. <i>Current Eye Research</i> , <b>2020</b> , 45, 921-930	2.9	10
55	Anti-MAG neuropathy: Role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. <i>Clinical Neurophysiology</i> , <b>2018</b> , 129, 2162-2169	4.3	9
54	Activity-induced weakness in recessive myotonia congenita with a novel (696+1G>A) mutation. <i>Clinical Neurophysiology</i> , <b>2006</b> , 117, 2064-8	4.3	9
53	Potassium control in chronic kidney disease: implications for neuromuscular function. <i>Internal Medicine Journal</i> , <b>2019</b> , 49, 817-825	1.6	9

## (2011-2020)

52	The Effect of Age, Gender and Body Mass Index on Tear Film Neuromediators and Corneal Nerves. <i>Current Eye Research</i> , <b>2020</b> , 45, 411-418	2.9	9
51	A Cross-Sectional Study of Sub-Basal Corneal Nerve Reduction Following Neurotoxic Chemotherapy. <i>Translational Vision Science and Technology</i> , <b>2021</b> , 10, 24	3.3	9
50	Nerve excitability in the rat forelimb: a technique to improve translational utility. <i>Journal of Neuroscience Methods</i> , <b>2017</b> , 275, 19-24	3	8
49	The impact of anticancer drugs on the ocular surface. Ocular Surface, 2020, 18, 403-417	6.5	8
48	Immune dysregulation in patients with carpal tunnel syndrome. Scientific Reports, 2017, 7, 8218	4.9	8
47	Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e553-4; author reply e555-6	2.2	8
46	Ion Channel Modulation as a Therapeutic Approach in Multiple Sclerosis. <i>Current Medicinal Chemistry</i> , <b>2015</b> , 22, 4366-78	4.3	8
45	Corneal nerve fiber loss in diabetes with chronic kidney disease. <i>Ocular Surface</i> , <b>2020</b> , 18, 178-185	6.5	8
44	Effect of fampridine on axonal excitability in multiple sclerosis. Clinical Neurophysiology, 2016, 127, 263	64.492	8
43	Relative contributions of diabetes and chronic kidney disease to neuropathy development in diabetic nephropathy patients. <i>Clinical Neurophysiology</i> , <b>2019</b> , 130, 2088-2095	4.3	7
42	Focal Ischaemic Infarcts Expand Faster in Cerebellar Cortex than Cerebral Cortex in a Mouse Photothrombotic Stroke Model. <i>Translational Stroke Research</i> , <b>2018</b> , 9, 643-653	7.8	7
41	The utility of the Total Neuropathy Score as an instrument to assess neuropathy severity in chronic kidney disease: A validation study. <i>Clinical Neurophysiology</i> , <b>2018</b> , 129, 889-894	4.3	7
40	The effects of large artery ischemia and subsequent recanalization on nerve excitability. <i>Muscle and Nerve</i> , <b>2011</b> , 44, 841-2	3.4	7
39	Intracranial and dermatological cryptococcal infection in an immunocompetent man. <i>Journal of Clinical Neuroscience</i> , <b>2004</b> , 11, 765-7	2.2	7
38	Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy-a randomised controlled trial. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 1103	-₹1910	7
37	Fampridine treatment and walking distance in multiple sclerosis: A randomised controlled trial. <i>Clinical Neurophysiology</i> , <b>2017</b> , 128, 93-99	4.3	6
36	Impaired energy-dependent processes underlie acute lead neuropathy. Muscle and Nerve, 2012, 46, 957	'- <b>6</b> .14	6
35	Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. <i>Clinical Neurophysiology</i> , <b>2011</b> , 122, 194-8	4.3	6

34	Association of corneal nerve loss with markers of axonal ion channel dysfunction in type 1 diabetes. <i>Clinical Neurophysiology</i> , <b>2020</b> , 131, 145-154	4.3	6
33	Evidence of Altered Peripheral Nerve Function in a Rodent Model of Diet-Induced Prediabetes. <i>Biomedicines</i> , <b>2020</b> , 8,	4.8	6
32	Comparative study to evaluate the effects of peritoneal and hemodialysis on peripheral nerve function. <i>Muscle and Nerve</i> , <b>2016</b> , 54, 58-64	3.4	6
31	Effects of hemodialysis on intraneural blood flow in end-stage kidney disease. <i>Muscle and Nerve</i> , <b>2018</b> , 57, 287-293	3.4	5
30	Transynaptic changes evident in peripheral axonal function after acute cerebellar infarct. <i>Cerebellum</i> , <b>2014</b> , 13, 669-76	4.3	5
29	Impact of the metabolic syndrome on peripheral nerve structure and function in type 2 diabetes. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 2074-2082	6	5
28	Sonographic assessment of nerve blood flow in diabetic neuropathy. <i>Diabetic Medicine</i> , <b>2020</b> , 37, 343-3	4 <b>9</b> .5	5
27	A cross-sectional study of ocular surface discomfort and corneal nerve dysfunction after paclitaxel treatment for cancer. <i>Scientific Reports</i> , <b>2021</b> , 11, 1786	4.9	5
26	Neuropathy and Other Neurological Problems in Chronic Kidney Disease <b>2014</b> , 343-352		4
25	Corneal nerve changes following treatment with neurotoxic anticancer drugs. <i>Ocular Surface</i> , <b>2021</b> , 21, 221-237	6.5	4
24	The Relationship between Dyslipidemia and Acute Axonal Function in Type 2 Diabetes Mellitus In Vivo. <i>PLoS ONE</i> , <b>2016</b> , 11, e0153389	3.7	4
23	Assessment of axonal excitability properties in two branches of the human facial nerve. <i>Journal of Neuroscience Methods</i> , <b>2016</b> , 274, 53-60	3	4
22	Associations between acute glucose control and peripheral nerve structure and function in type 1 diabetes. <i>Diabetic Medicine</i> , <b>2020</b> , 37, 1553-1560	3.5	4
21	Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol. <i>BMJ Open</i> , <b>2019</b> , 9, e023736	3	3
20	Changes in long term peripheral nerve biophysical properties in childhood cancer survivors following neurotoxic chemotherapy. <i>Clinical Neurophysiology</i> , <b>2020</b> , 131, 783-790	4.3	3
19	Motor unit number estimation of facial muscles using the M Scan-Fit method. <i>Muscle and Nerve</i> , <b>2020</b> , 62, 555-558	3.4	2
18	Altered axonal excitability properties in facial palsy. <i>Muscle and Nerve</i> , <b>2018</b> , 57, 268-272	3.4	2
17	Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. <i>Muscle and Nerve</i> , <b>2018</b> , 57, 615-621	3.4	2

#### LIST OF PUBLICATIONS

16	The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 1189-90; author reply 1191-2	3.5	2	
15	Another cause of occupational entrapment neuropathy: la main du cuisinier (the chefß hand). <i>Journal of Clinical Neurophysiology</i> , <b>2009</b> , 26, 129-31	2.2	2	
14	Cytoplasmic body myopathy masquerading as motor neuron disease. <i>Muscle and Nerve</i> , <b>2004</b> , 30, 667-7	723.4	2	
13	Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel. <i>Scientific Reports</i> , <b>2021</b> , 11, 22884	4.9	2	
12	Altered peripheral nerve structure and function in latent autoimmune diabetes in adults. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2020</b> , 36, e3260	7.5	2	
11	The provision of written information and its effect on levels of pain and anxiety during electrodiagnostic studies: A randomised controlled trial. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196917	3.7	2	
10	In Vivo Electrophysiological Measurement of the Rat Ulnar Nerve with Axonal Excitability Testing. <i>Journal of Visualized Experiments</i> , <b>2018</b> ,	1.6	1	
9	Peripheral Neuropathy: An Important Contributor To Physical Limitation And Morbidity In Stage 3-4 Chronic Kidney Disease. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> ,	4.3	1	
8	Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure: A Randomized Controlled Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2021</b> , 16, 1365-1375	6.9	1	
7	Effect of exenatide on peripheral nerve excitability in type 2 diabetes. <i>Clinical Neurophysiology</i> , <b>2021</b> , 132, 2532-2539	4.3	1	
6	The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial <i>Diabetes and Metabolism</i> , <b>2022</b> , 101331	5.4	O	
5	Tear film and ocular surface neuropeptides: Characteristics, synthesis, signaling and implications for ocular surface and systemic diseases <i>Experimental Eye Research</i> , <b>2022</b> , 218, 108973	3.7	O	
4	Automated analysis of corneal nerve tortuosity in diabetes: implications for neuropathy detection. <i>Australasian journal of optometry, The</i> ,1-7	2.7	O	
3	Disorders of vision in multiple sclerosis. Australasian journal of optometry, The, <b>2021</b> , 1-10	2.7	O	
2	The Impact of Post-Tear Collection Storage on Tear Film Substance P Concentration <i>Current Eye Research</i> , <b>2022</b> , 1-5	2.9	O	
1	Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders. <i>Pharmaceuticals</i> , <b>2022</b> , 15, 607	5.2	O	